Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia

Blood (2024) 144 (23): 2417–2431.

https://doi.org/10.1182/blood.2024024281

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

Blood (2024) 144 (Supplement 1): 525.

https://doi.org/10.1182/blood-2024-212106

Published: 2024

Journal Articles

Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Blood (2024) 144 (Supplement 1): 612.

https://doi.org/10.1182/blood-2024-202665

Published: 2024

Journal Articles

Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 473.

https://doi.org/10.1182/blood-2024-201626

Published: 2024

Journal Articles

KMT2A -Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation

Venkata Sesha Sai Abhinav Ayyadevara, Gerald Wertheim, John Chukinas, Joseph Loftus, Sung June Lee, Anil Kumar, Srividya Swaminathan, Rahul S Bhansali, Wayne Childers, Huimin Geng, Thomas A Milne, Xianxin Hua, Kathrin M. Bernt, Thierry Besson, Junwei Shi, John D. Crispino, Martin P Carroll, Sarah K. Tasian, Christian Hurtz

Blood (2024) 144 (Supplement 1): 1455.

https://doi.org/10.1182/blood-2024-206134

Published: 2024

Journal Articles

Defining Oncogenic Transcriptional Networks Regulated By LDB1 in T-Cell Acute Lymphoblastic Leukemia

Rahul S Bhansali, Nicholas Aboreden, Siqing Wang, Cheryl A. Keller, Belinda M. Giardine, Ross C. Hardison, Gerd A. Blobel

Blood (2024) 144 (Supplement 1): 2740.

https://doi.org/10.1182/blood-2024-201055

Published: 2024

Journal Articles

Somatic Mutation Screening in Adult Patients with Myeloid Malignancies Provides Insights into Likely Germline Variants

Rahul S. Bhansali, Xin Wang, Valentina Mattfeld, Dana F. Clark, Jennifer JD Morrissette, Martin Carroll, Daria Babushok, Ximena Jordan Bruno

Blood (2023) 142 (Supplement 1): 5665.

https://doi.org/10.1182/blood-2023-174488

Published: 2023

Journal Articles

Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities

Blood (2023) 142 (Supplement 1): 2407.

https://doi.org/10.1182/blood-2023-183041

Published: 2023

Journal Articles

Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma

Blood (2023) 142 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2023-183011

Published: 2023

Journal Articles

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Anita Kumar, Ashlee Joseph, Brian T. Hill, Taylor R. Brooks, David A. Bond, Kami J. Maddocks, Alexey Danilov, Christine McCarthy, Jia Ruan, Imran A. Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Evguenia Ouchveridze, Aung M. Tun, Philip Young, Craig A. Portell, Zoey I. Harris, Javier L. Munoz, Patrick M. Reagan, Georgio Pongas, Izidore S. Lossos, Christine E. Ryan, Reid W. Merryman, Firas Baidoun, Muhamad Alhaj Moustafa, Drew Gerber, Sabarish R. Ayyappan, Brian K. Link, Arash Velayati, Irl Brian Greenwell, Lauren G Banaszak, Priyanka A Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur Narkhede, Amitkumar N. Mehta, Preetesh Jain, Michael L. Wang, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Laveniya Kugathasan, Diego Villa, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Blood (2023) 142 (Supplement 1): 300.

https://doi.org/10.1182/blood-2023-182942

Published: 2023

Journal Articles

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1481–1484.

https://doi.org/10.1182/blood-2022-160090

Published: 2022

Journal Articles

Characterizing Mature T-Cell Lymphoma Patients' Outcomes By Race

Miao Cao, Rahul S. Bhansali, Wenrui Li, Qi Long, Elise A. Chong, James N. Gerson, Daniel J. Landsburg, Sunita Nasta, Jakub Svoboda, Stephen J. Schuster, Stefan K. Barta

Blood (2022) 140 (Supplement 1): 12013–12015.

https://doi.org/10.1182/blood-2022-168032

Published: 2022

Journal Articles

Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy

Blood (2022) 140 (Supplement 1): 2416–2418.

https://doi.org/10.1182/blood-2022-163822

Published: 2022

Journal Articles

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

V. S. S. Abhinav Ayyadevara, Gerald Wertheim, John Chukinas, Joseph Patrick Loftus, Sung June Lee, Anil Kumar, Rahul S. Bhansali, Srividya Swaminathan, Thierry Besson, Junwei Shi, John D. Crispino, Sarah K Tasian, Martin P. Carroll, Christian Hurtz

Blood (2022) 140 (Supplement 1): 3486–3488.

https://doi.org/10.1182/blood-2022-162782

Published: 2022

Journal Articles

Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices

Blood (2021) 138 (Supplement 1): 532.

https://doi.org/10.1182/blood-2021-147033

Published: 2021

Journal Articles

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

Christian Hurtz, Gerald Wertheim, John Chukinas, Joseph Patrick Loftus, Sung June Lee, Anil Kumar, Rahul S. Bhansali, Srividya Swaminathan, Thierry Besson, Junwei Shi, John D. Crispino, Sarah K Tasian, Martin P. Carroll

Blood (2021) 138 (Supplement 1): 506.

https://doi.org/10.1182/blood-2021-144476

Published: 2021

Journal Articles

A Multi-Institutional Retrospective Analysis of T-Cell Lymphomas with Central Nervous System Relapse

Blood (2021) 138 (Supplement 1): 1382.

https://doi.org/10.1182/blood-2021-148868

Published: 2021

Journal Articles

DYRK1A Is Required to Alleviate Replication Stress in KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Martin P. Carroll, MD, Sarah K Tasian, MD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, MDPhD, Sung June Lee, BA, Anil Kumar, PhD, Anne Lehman, Joseph Patrick Loftus, BS, Grace Jeschke, PhD, John D. Crispino, PhD, Thierry Besson, PhD, Junwei Shi, PhD, Srividya Swaminathan, PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-141258

Published: 2020

Journal Articles

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, Anne Lehman, Grace Jeschke, PhD, John D. Crispino, PhD MBA, Thierry Besson, PhD, Sarah K. Tasian, MD, Martin Carroll, MD

Blood (2019) 134 (Supplement_1): 2742.

https://doi.org/10.1182/blood-2019-123475

Published: 2019

Journal Articles

The Chromosome 21 Kinase DYRK1A and Its Substrate FOXO1 Constitute a Novel Therapeutic Pathway in B-ALL

Rahul S. Bhansali, Malini Rammohan, MS, Ji Heon Paul Lee, MD PhD, Sebastien Malinge, PhD, Yi-Chien Tsai, Nobuko Hijiya, MD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD, Corinne Fruit, Thierry Besson, PhD, John D. Crispino, PhD MBA

Blood (2018) 132 (Supplement 1): 548.

https://doi.org/10.1182/blood-2018-99-119854

Published: 2018

NARROW

Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia

Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma

KMT2A -Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation

Defining Oncogenic Transcriptional Networks Regulated By LDB1 in T-Cell Acute Lymphoblastic Leukemia

Somatic Mutation Screening in Adult Patients with Myeloid Malignancies Provides Insights into Likely Germline Variants

Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities

Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Characterizing Mature T-Cell Lymphoma Patients' Outcomes By Race

Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

A Multi-Institutional Retrospective Analysis of T-Cell Lymphomas with Central Nervous System Relapse

DYRK1A Is Required to Alleviate Replication Stress in KMT2A -Rearranged Acute Lymphoblastic Leukemia

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

The Chromosome 21 Kinase DYRK1A and Its Substrate FOXO1 Constitute a Novel Therapeutic Pathway in B-ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only